Advanced

Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

Kasteng, Frida; Erlanson, Martin; Hagberg, Hans; Kimby, Eva; Relander, Thomas LU and Lundkvist, Jonas (2008) In Acta Oncologica 47(6). p.1029-1036
Abstract
Introduction. Rituximab has significantly improved the prognosis for patients with both indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out to assess the cost-effectiveness in Sweden of rituximab as maintenance therapy for patients with follicular lymphoma in remission after second line therapy. Materials and methods. The incremental cost and effectiveness of rituximab maintenance therapy versus observation were evaluated in a health-state transition model. Primary effect measures were quality-adjusted life-years (QALY) and life-years gained (LYG). Model state transitions were calculated based on progression-free and overall survival data from the EORTC20981 trial. The analysis was made from the... (More)
Introduction. Rituximab has significantly improved the prognosis for patients with both indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out to assess the cost-effectiveness in Sweden of rituximab as maintenance therapy for patients with follicular lymphoma in remission after second line therapy. Materials and methods. The incremental cost and effectiveness of rituximab maintenance therapy versus observation were evaluated in a health-state transition model. Primary effect measures were quality-adjusted life-years (QALY) and life-years gained (LYG). Model state transitions were calculated based on progression-free and overall survival data from the EORTC20981 trial. The analysis was made from the perspective of the healthcare provider, including direct medical costs presented in (sic), 2007 value. Effects and costs were discounted at a 3% annual rate. The stability of the base case results were tested in one-way and probabilistic sensitivity analyses. Results. The evaluation assessed rituximab maintenance therapy to be associated with an incremental cost per QALY gained of (sic)12 600 and an incremental cost per LYG of (sic)11 200. The average discounted life expectancy for patients on rituximab maintenance was 1.0 year longer than for patients on observation (5.96 vs. 4.94 years). Rituximab maintenance was associated with an additional 0.9 QALY, and total costs per patient were (sic)11 500 higher in the treatment arm, compared to observation. Discussion. The results indicate that rituximab maintenance treatment after successful induction therapy for patients with relapsed/refractory follicular lymphoma in Sweden is cost-effective compared to observation. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
47
issue
6
pages
1029 - 1036
publisher
Taylor & Francis
external identifiers
  • wos:000258905100006
  • scopus:51149091885
ISSN
1651-226X
DOI
10.1080/02841860802120028
language
English
LU publication?
yes
id
e554a411-231f-4678-8f46-de0e0d7baea8 (old id 1247878)
date added to LUP
2008-11-10 10:34:01
date last changed
2017-07-30 04:07:00
@article{e554a411-231f-4678-8f46-de0e0d7baea8,
  abstract     = {Introduction. Rituximab has significantly improved the prognosis for patients with both indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out to assess the cost-effectiveness in Sweden of rituximab as maintenance therapy for patients with follicular lymphoma in remission after second line therapy. Materials and methods. The incremental cost and effectiveness of rituximab maintenance therapy versus observation were evaluated in a health-state transition model. Primary effect measures were quality-adjusted life-years (QALY) and life-years gained (LYG). Model state transitions were calculated based on progression-free and overall survival data from the EORTC20981 trial. The analysis was made from the perspective of the healthcare provider, including direct medical costs presented in (sic), 2007 value. Effects and costs were discounted at a 3% annual rate. The stability of the base case results were tested in one-way and probabilistic sensitivity analyses. Results. The evaluation assessed rituximab maintenance therapy to be associated with an incremental cost per QALY gained of (sic)12 600 and an incremental cost per LYG of (sic)11 200. The average discounted life expectancy for patients on rituximab maintenance was 1.0 year longer than for patients on observation (5.96 vs. 4.94 years). Rituximab maintenance was associated with an additional 0.9 QALY, and total costs per patient were (sic)11 500 higher in the treatment arm, compared to observation. Discussion. The results indicate that rituximab maintenance treatment after successful induction therapy for patients with relapsed/refractory follicular lymphoma in Sweden is cost-effective compared to observation.},
  author       = {Kasteng, Frida and Erlanson, Martin and Hagberg, Hans and Kimby, Eva and Relander, Thomas and Lundkvist, Jonas},
  issn         = {1651-226X},
  language     = {eng},
  number       = {6},
  pages        = {1029--1036},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden},
  url          = {http://dx.doi.org/10.1080/02841860802120028},
  volume       = {47},
  year         = {2008},
}